Comparative analysis of immunophenotypic methods for the assessment of minimal residual disease in hairy cell leukemia

被引：0
|
作者：
Bengiò, R [1 ]
Narbaitz, MI [1 ]
Sarmiento, MA [1 ]
Palacios, MF [1 ]
Scolnik, MP [1 ]
机构：
[1] Acad Nacl Med, IIHEMA, Clin Hematol, Inst Invest Hematol Mariano R Castex, RA-1425 Buenos Aires, DF, Argentina
来源：
HAEMATOLOGICA | 2000年 / 85卷 / 11期
关键词：
MRD in hairy cell leukemia; pow cytometry; immunohistochemistry;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Hairy cell leukemia patients in complete remission may have minimal residual disease (MRD), We performed flow cytometry (FCM) and immunohistochemistry (IHC) to detect MRD in 15 patients. FCM and IHC detected MRD+ in 64% and 46 % of the patients, respectively. MRD+ did not predict relapse.
引用
收藏
页码：1227 / 1229
页数：3
相关论文
共 50 条
  • [31] Hairy cell leukemia. An alternative method for the detection of minimal residual disease using flow cytometry.
    Bengio, R
    Narbaitz, M
    Palacios, F
    Scolnik, M
    Sarmiento, M
    MEDICINA-BUENOS AIRES, 2000, 60 : 71 - 76
  • [32] Comparative Assessment Of Minimal Residual Disease In Acute Myeloid Leukemia By Flow Cytometry and Molecular Genetics
    Kern, Wolfgang
    Rose, Dominic
    Haferlach, Claudia
    Haferlach, Torsten
    Schnittger, Susanne
    BLOOD, 2013, 122 (21)
  • [33] Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia
    Zeijlemaker, W.
    Kelder, A.
    Oussoren-Brockhoff, Y. J. M.
    Scholten, W. J.
    Snel, A. N.
    Veldhuizen, D.
    Cloos, J.
    Ossenkoppele, G. J.
    Schuurhuis, G. J.
    LEUKEMIA, 2016, 30 (03) : 708 - 715
  • [34] Hairy Cell Leukemia: Hematological and Immunophenotypic Profile of 13 Patients
    Bhatti, Vandana
    Kaur, Gurpreet
    Ahuja, Aarzoo
    Isaacs, Roma
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
  • [35] Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia
    W Zeijlemaker
    A Kelder
    Y J M Oussoren-Brockhoff
    W J Scholten
    A N Snel
    D Veldhuizen
    J Cloos
    G J Ossenkoppele
    G J Schuurhuis
    Leukemia, 2016, 30 : 708 - 715
  • [36] Minimal Residual Disease Assessment in Lymphoma: Methods and Applications
    Herrera, Alex F.
    Armand, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (34) : 3877 - +
  • [37] Minimal residual disease assessment in chronic lymphocytic leukemia.
    Maloum, K
    Magnac, C
    Sutton, L
    Leblond, V
    Cazin, B
    Boccaccio, C
    Davi, F
    Binet, JL
    MerleBeral, H
    Dighiero, G
    BLOOD, 1996, 88 (10) : 297 - 297
  • [38] IMPORTANCE OF IMMUNOPHENOTYPIC CHANGES IN THE ESTIMATION OF MINIMAL RESIDUAL DISEASE OF PATIENTS WITH B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN THE AGE OF STANDARDIZATION
    Sarmiento Palao, H.
    Martirena, F.
    Manresa Manresa, P.
    Lopez Castano, F.
    Garcia Hernandez, C.
    Arranz, E.
    Diaz Rodriguez, V
    Taso, M.
    Lopez Iniesta, S.
    Moscardo, C.
    Fernandez Abellan, P.
    Gil Cortes, C.
    Botella, C.
    Mauricio, A.
    Verdu Belmar, J.
    De Paz, F.
    Lucas, J.
    Marco, P.
    Tarin, F.
    HAEMATOLOGICA, 2017, 102 : 133 - 134
  • [39] Comparison of methods for assessment of minimal residual disease in childhood B-lineage acute lymphoblastic leukemia
    Brisco, MJ
    Sykes, PJ
    Hughes, E
    Neoh, SH
    Snell, LE
    Dolman, G
    Peng, LM
    Toogood, IRG
    Cheney, K
    Rice, MS
    Story, CJ
    Morley, AA
    LEUKEMIA, 2001, 15 (03) : 385 - 390
  • [40] Comparison of methods for assessment of minimal residual disease in childhood B-lineage acute lymphoblastic leukemia
    MJ Brisco
    PJ Sykes
    E Hughes
    S-H Neoh
    LE Snell
    G Dolman
    L-M Peng
    IRG Toogood
    K Cheney
    MS Rice
    CJ Story
    AA Morley
    Leukemia, 2001, 15 : 385 - 390
12345